摘要
目的探讨康复新液联合健康教育干预治疗慢性糜烂性胃炎的临床效果。方法将收治的慢性糜烂性胃炎患者148例随机分为对照组和观察组,每组74例。对照组给予康复新液治疗,观察组在对照组基础上加强健康教育指导,比较两组患者临床疗效、临床症状积分和血清热休克蛋白(HSP)70 m RNA水平。结果观察组临床有效率为87.84%,显著高于对照组的68.92%(P<0.05);治疗后两组患者反酸、嗳气和上腹痛症状积分显著低于治疗前(P<0.05),且观察组显著低于对照组(P<0.05);两组患者治疗后HSP70 m RNA水平显著高于治疗前,且观察组显著高于对照组(P<0.05)。结论康复新液联合健康教育干预治疗慢性糜烂性胃炎效果显著,可有效改善临床症状,诱导HSP70表达,优于单用康复新液治疗。
Objective To investigate the clinical effect of the health education combined with Kangfuxin Solution in treating chronic ero-sive gastritis. Methods A total of 148 patients with chronic erosive gastritis were randomly divided into the control group and the ob-servation group, 74 cases in each group. The control group was given Kangfuxin Solution, while on this basis the observation group was strengthened by the health education guidance. The clinical efficacies, clinical symptom scores and HSP70 mRNA levels were compared between the two groups. Results The clinical efficacy in the observation group was significantly higher than that in the control group （ 87. 84% vs. 68. 92%） with statistical difference between the two groups （ P〈 0. 05 ）;the symptom scores of acid reflux, belching and upper abdominal pain after treatment were significantly lower than those before treatment （ P〈 0. 05 ） , moreover the observation group was significantly lower than the control group with statistically significant difference （ P〈 0. 05 ）;the HSP70 mRNA level after treatment was significantly higher than that before treatment, moreover the observation group was significantly higher than the control group with statistical difference （ P〈 0. 05 ） . Conclusion The health education combined with Kangfuxin Solution has significant effect in treating chronic erosive gastritis, effectively improves the clinical symptoms, induces the expression of HSP70, thus plays the role for treating chronic erosive gastritis, which is better than Kangfuxin Solution alone.
出处
《中国药业》
CAS
2015年第9期99-100,共2页
China Pharmaceuticals
